Vibrio Infections Medication
- Author: Hoi Ho, MD; Chief Editor: Michael Stuart Bronze, MD more...
In adults with noncholera Vibrio infections other than gastroenteritis, the combination of a third-generation cephalosporin (eg, ceftazidime, cefotaxime, ceftriaxone) and tetracycline or one of its analogues (eg, doxycycline) or a single-agent regimen with a fluoroquinolone (eg, levofloxacin, ciprofloxacin) is the therapy of choice.[32, 33]
Among children with serious noncholera Vibrio infections in whom tetracycline and fluoroquinolone are contraindicated, trimethoprim-sulfamethoxazole plus an aminoglycoside (eg, gentamicin) is recommended.
Analyzing the efficacy of 3 antibiotic regimens (group 1, a third-generation cephalosporin; group 2, a third-generation cephalosporin plus minocycline; group 3, a fluoroquinolone with or without minocycline) in terms of patient outcomes in the treatment of 89 cases of V vulnificus necrotizing fasciitis, authors reported that a fluoroquinolone or the combination of a third-generation cephalosporin plus minocycline are antibiotics of choice in lowering mortality rates (61% in group 1 vs 14% in group 2, P = 0.0003; 61% in group 1 vs 14% in group 3, P = 0.00027).
Another alternative regimen with documented synergism in vivo study on mice is cefotaxime and minocycline.
In a retrospective chart review of 93 patients hospitalized with serious Vibrio infections, the combination of a third-generation cephalosporin and tetracycline or its analogue was an independent factor for lower mortality (OR, 0.337; 95% CI, 0.007-0.192; P < .001).
Tigecycline, a novel glycylcycline, has a potent in vitro antimicrobial effect against Vibrio species. Other newer antibiotics such as daptomycin and linezolid that were approved for the treatment of serious skin and soft-tissue infections have not been studied in serious Vibrio infections. Therefore, the authors do not currently recommend the use of these antibiotics in the treatment of serious Vibrio infections.
Adjuvant therapy: Recombinant human activated protein C (drotrecogin alfa activated) has been used as an adjuvant therapy in patients with severe sepsis who scored 25 or more on the Acute Physiology and Chronic Health Evaluation (APACHE II). A few patients with V vulnificus sepsis who were successfully treated with antibiotics, surgical debridement, and recombinant human activated protein C were reported. In view of serious bleeding associated with the continuous infusion of recombinant human activated protein C and the potential requirement for repeated surgical debridement in patients with V vulnificus sepsis, routine use of this adjuvant therapy is not recommended.
Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting. Antibiotic combinations are usually recommended for serious gram-negative bacillary infections. This approach ensures coverage for a broad range of organisms and polymicrobial infections. In addition, resistance from bacterial subpopulations is prevented, and additive or synergistic effects are provided. Once organisms and sensitivities are known, the use of antibiotic monotherapy is recommended.
Inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.
Antipseudomonal penicillin plus beta-lactamase inhibitor. Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active multiplication.
Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active growth. Antipseudomonal penicillin plus beta-lactamase inhibitor provides coverage against most gram-positive, gram-negative, and anaerobic bacteria.
Fluoroquinolone with activity against pseudomonads, streptococci, MRSA, Staphylococcus epidermidis, and most gram-negative organisms but no activity against anaerobes. Inhibits bacterial DNA synthesis and, consequently, growth.
For septicemia and treatment of gynecologic infections caused by susceptible organisms. Arrests bacterial cell wall synthesis, which in turn inhibits bacterial growth. Third-generation cephalosporin with gram-negative spectrum. Lower efficacy against gram-positive organisms.
2011 Estimates of foodborne illness in the united states. [Full Text].
Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States--major pathogens. Emerg Infect Dis. 2011 Jan. 17(1):7-15. [Medline].
Vital Signs: Incidence and Trends of Infection with Pathogens Transmitted Commonly Through Food --- Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 1996—2010. [Full Text].
FoodNet's Progress Reports. 2013 Progress Report on Six Key Pathogens Compared to 2006-2008. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/foodnet/data/trends/trends-2013-progress.html. Accessed: September 26, 2014.
Marano NN, Daniels NA, Easton AN, McShan A, Ray B, Wells JG. A survey of stool culturing practices for vibrio species at clinical laboratories in Gulf Coast states. J Clin Microbiol. 2000 Jun. 38(6):2267-70. [Medline].
Dechet AM, Yu PA, Koram N, Painter J. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis. 2008 Apr 1. 46(7):970-6. [Medline].
Centers for Disease Control and Prevention (CDC). Vibrio illnesses after Hurricane Katrina--multiple states, August-September 2005. MMWR Morb Mortal Wkly Rep. 2005 Sep 23. 54(37):928-31. [Medline].
Shapiro RL, Altekruse S, Hutwagner L. The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group. J Infect Dis. 1998 Sep. 178(3):752-9. [Medline].
Richards GP, Watson MA, Boyd EF, Burkhardt W 3rd, Lau R, Uknalis J. Seasonal levels of the Vibrio predator bacteriovorax in atlantic, pacific, and gulf coast seawater. Int J Microbiol. 2013. 2013:375371. [Medline].
Brennt CE, Wright AC, Dutta SK. Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation. J Infect Dis. 1991 Nov. 164(5):1030-2. [Medline].
Hor LI, Chang TT, Wang ST. Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels. J Infect Dis. 1999 Jan. 179(1):275-8. [Medline].
Miyoshi S, Nakazawa H, Kawata K, Tomochika K, Tobe K, Shinoda S. Characterization of the hemorrhagic reaction caused by Vibrio vulnificus metalloprotease, a member of the thermolysin family. Infect Immun. 1998 Oct. 66(10):4851-5. [Medline].
Shao CP, Hor LI. Metalloprotease is not essential for Vibrio vulnificus virulence in mice. Infect Immun. 2000 Jun. 68(6):3569-73. [Medline].
Hilton T, Rosche T, Froelich B, Smith B, Oliver J. Capsular polysaccharide phase variation in Vibrio vulnificus. Appl Environ Microbiol. 2006 Nov. 72(11):6986-93. [Medline].
Lee SE, Kim SY, Kim CM, Kim MK, Kim YR, Jeong K. The pyrH gene of Vibrio vulnificus is an essential in vivo survival factor. Infect Immun. 2007 Jun. 75(6):2795-801. [Medline].
Wong TW, Wang YY, Sheu HM, Chuang YC. Bactericidal effects of toluidine blue-mediated photodynamic action on Vibrio vulnificus. Antimicrob Agents Chemother. 2005 Mar. 49(3):895-902. [Medline].
Shirai H, Ito H, Hirayama T, Nakamoto Y, Nakabayashi N, Kumagai K. Molecular epidemiologic evidence for association of thermostable direct hemolysin (TDH) and TDH-related hemolysin of Vibrio parahaemolyticus with gastroenteritis. Infect Immun. 1990 Nov. 58(11):3568-73. [Medline].
Nishibuchi M, Fasano A, Russell RG, Kaper JB. Enterotoxigenicity of Vibrio parahaemolyticus with and without genes encoding thermostable direct hemolysin. Infect Immun. 1992 Sep. 60(9):3539-45. [Medline].
Vibrio parahaemolyticus infections associated with consumption of raw shellfish--three states, 2006. MMWR Morb Mortal Wkly Rep. 2006 Aug 11. 55(31):854-6. [Medline].
Newton AE, Garrett N, Stroika SG, Halpin JL, Turnsek M, Mody RK. Increase in Vibrio parahaemolyticus infections associated with consumption of Atlantic Coast shellfish--2013. MMWR Morb Mortal Wkly Rep. 2014 Apr 18. 63(15):335-6. [Medline].
Centers for Disease Control and Prevention. Non-O1 and Non-O139 Vibrio cholerae Infections. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/cholera/non-01-0139-infections.html. Accessed: September 26, 2014.
Tsai YH, Huang TJ, Hsu RW, Weng YJ, Hsu WH, Huang KC. Necrotizing soft-tissue infections and primary sepsis caused by Vibrio vulnificus and Vibrio cholerae non-O1. J Trauma. 2009 Mar. 66(3):899-905. [Medline].
Ralston EP, Kite-Powell H, Beet A. An estimate of the cost of acute health effects from food- and water-borne marine pathogens and toxins in the USA. J Water Health. 2011 Dec. 9(4):680-94. [Medline].
Osaka K, Komatsuzaki M, Takahashi H, Sakano S, Okabe N. Vibrio vulnificus septicaemia in Japan: an estimated number of infections and physicians' knowledge of the syndrome. Epidemiol Infect. 2004 Oct. 132(5):993-6. [Medline].
Haq SM, Dayal HH. Chronic liver disease and consumption of raw oysters: a potentially lethal combination--a review of Vibrio vulnificus septicemia. Am J Gastroenterol. 2005 May. 100(5):1195-9. [Medline].
Chen SC, Chan KS, Chao WN, Wang PH, Lin DB, Ueng KC. Clinical outcomes and prognostic factors for patients with Vibrio vulnificus infections requiring intensive care: a 10-yr retrospective study. Crit Care Med. 2010 Oct. 38(10):1984-90. [Medline].
Liu JW, Lee IK, Tang HJ, Ko WC, Lee HC, Liu YC. Prognostic Factors and Antibiotics in Vibrio vulnificus Septicemia. Arch Intern Med. 2006 Oct 23. 166(19):2117-23. [Medline].
Dadisman TA Jr, Nelson R, Molenda JR. Vibrio parahaemolyticus gastroenteritis in Maryland. I. Clinical and epidemiologic aspects. Am J Epidemiol. 1972 Dec. 96(6):414-26. [Medline].
Howard RJ, Lieb S. Soft-tissue infections caused by halophilic marine vibrios. Arch Surg. 1988 Feb. 123(2):245-9. [Medline].
Klontz KC, Lieb S, Schreiber M. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med. 1988 Aug 15. 109(4):318-23. [Medline].
Centers for Disease Control and Prevention. Management of Vibrio vulnificus Wound Infections After a Disaster. Centers for Disease Control and Prevention. Available at http://www.bt.cdc.gov/disasters/disease/vibriofaq.asp. Accessed: September 26, 2014.
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jul 15. 59(2):e10-52. [Medline].
Chen SC, Lee YT, Tsai SJ, Chan KS, Chao WN, Wang PH. Antibiotic therapy for necrotizing fasciitis caused by Vibrio vulnificus: retrospective analysis of an 8 year period. J Antimicrob Chemother. 2012 Feb. 67(2):488-93. [Medline].
Chuang YC, Ko WC, Wang ST, Liu JW, Kuo CF, Wu JJ. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother. 1998 Jun. 42(6):1319-22. [Medline].
Anand RG, Lopez FA, deBoisblanc B. Vibrio vulnificus sepsis successfully treated with antibiotics, surgical debridement, and recombinant human activated protein C. J La State Med Soc. 2004 May-Jun. 156(3):130-3; quiz 133. [Medline].
Mouzin E, Mascola L, Tormey MP. Prevention of Vibrio vulnificus infections. Assessment of regulatory educational strategies. JAMA. 1997 Aug 20. 278(7):576-8. [Medline].
Lee HS, Choi S, Shin H, Lee JH, Choi SH. Vibrio vulnificus bacteriophage SSP002 as a possible biocontrol agent. Appl Environ Microbiol. 2014 Jan. 80(2):515-24. [Medline].
Kingsley DH. High Pressure Processing of Bivalve Shellfish and HPP’s Use as a Virus Intervention. Foods. 2014. 3(2):336-50.
Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--selected sites, United States, 2003. MMWR Morb Mortal Wkly Rep. 2004 Apr 30. 53(16):338-43. [Medline].
DePaola A, Capers GM, Alexander D. Densities of Vibrio vulnificus in the intestines of fish from the U.S. Gulf Coast. Appl Environ Microbiol. 1994 Mar. 60(3):984-8. [Medline].
Hiransuthikul N, Tantisiriwat W, Lertutsahakul K, Vibhagool A, Boonma P. Skin and soft-tissue infections among tsunami survivors in southern Thailand. Clin Infect Dis. 2005 Nov 15. 41(10):e93-6. [Medline].
Hlady WG, Klontz KC. The epidemiology of Vibrio infections in Florida, 1981-1993. J Infect Dis. 1996 May. 173(5):1176-83. [Medline].
Hollis DG, Weaver RE, Baker CN. Halophilic Vibrio species isolated from blood cultures. J Clin Microbiol. 1976 Apr. 3(4):425-31. [Medline].
Richards GP, Watson MA, Boyd EF, Burkhardt W 3rd, Lau R, Uknalis J, et al. Seasonal levels of the Vibrio predator bacteriovorax in atlantic, pacific, and gulf coast seawater. Int J Microbiol. 2013. 2013:375371. [Medline]. [Full Text].
Scallan E, Griffin PM, Angulo FJ, Tauxe RV, Hoekstra RM. Foodborne illness acquired in the United States--unspecified agents. Emerg Infect Dis. 2011 Jan. 17(1):16-22. [Medline].
Summary of Notifiable Diseases in United States, 2009. [Full Text].
Tao Z, Larsen AM, Bullard SA, Wright AC, Arias CR. Prevalence and population structure of Vibrio vulnificus on fishes from the northern Gulf of Mexico. Appl Environ Microbiol. 2012 Nov. 78(21):7611-8. [Medline]. [Full Text].
|Infection Type||Noncholera Vibrio Species||Cytotoxins/Enzymes|
Non-01 V cholerae
|Wound infection||V alginolyticus
Non-01 V cholerae
Non-01 V cholerae
|Non-01 V cholerae||67||9||15||…|
|Clinical Presentation||Symptoms (Frequency)|
Abdominal cramps (89%)
Bloody stools (29%)
|Wound infection||Swelling (100%)
Gangrene (< 10%)
Hypothermia (< 10%)
Acute respiratory distress syndrome (< 5%)
Multiple organ dysfunction (30-50%)